HeXun Biosciences Co (ROCO:6986) Ending Cash Position: NT$417.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
42 GF Score
Price NT$40.35
GF Value NT$110.18
Valuation Significantly Undervalued
View Full Analysis

What is HeXun Biosciences Co Ending Cash Position?

HeXun Biosciences Co ROCO:6986 -0.25% 42 Ending Cash Position is NT$417.8 Mil as of Jun. 2026. GuruFocus rates ROCO:6986 with a GF Score™ of 42/100 and a GF Value™ of NT$110.18 (Significantly Undervalued).

HeXun Biosciences Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$417.8 Mil.

HeXun Biosciences Co's quarterly Ending Cash Position declined from Jun. 2025 (NT$199.0 Mil) to Dec. 2025 (NT$0.0 Mil) but then increased from Dec. 2025 (NT$0.0 Mil) to Jun. 2026 (NT$417.8 Mil).

HeXun Biosciences Co's annual Ending Cash Position declined from Dec. 2023 (NT$257.7 Mil) to Dec. 2024 (NT$201.0 Mil) but then increased from Dec. 2024 (NT$201.0 Mil) to Dec. 2025 (NT$208.2 Mil).

HeXun Biosciences Co Ending Cash Position Related Terms

HeXun Biosciences Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co Ending Cash Position Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 85.03 119.74 257.67 200.99 208.20

HeXun Biosciences Co Semi-Annual Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 198.95 0.00 417.82
ROCO:6986
42GF Score
HeXun Biosciences Co Ltd ROCO:6986
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeXun Biosciences Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

HeXun Biosciences Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=200.992+7.205
=208.2

HeXun Biosciences Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=118.249+299.569
=417.8

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$417.8 Mil mean?
HeXun Biosciences Co (ROCO:6986) has a Ending Cash Position of NT$417.8 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Ending Cash Position too high?
HeXun Biosciences Co's current Ending Cash Position is NT$417.8 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Ending Cash Position compare to VRTX and REGN?
HeXun Biosciences Co's Ending Cash Position of NT$417.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Ending Cash Position is NT$417.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, HeXun Biosciences Co (ROCO:6986) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$110.18, compared to a current price of NT$40.35 — trading 63.4% below its estimated fair value. The current Ending Cash Position is NT$417.8 Mil. HeXun Biosciences Co's overall GF Score™ is 42/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Ending Cash Position is NT$417.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HeXun Biosciences Co (ROCO:6986) Overvalued in 2026?

Based on GuruFocus' analysis, HeXun Biosciences Co stock appears to be undervalued. The current stock price of NT$40.35 is trading 63.4% below its estimated GF Value™ of NT$110.18. GuruFocus considers HeXun Biosciences Co to be Significantly Undervalued.

Key valuation signals for ROCO:6986:

  • Ending Cash Position: NT$417.8 Mil
  • GF Value™: NT$110.18 vs. price of NT$40.35 (63.4% below fair value)
  • GF Score™: 42/100

No single metric tells the full story. See the ROCO:6986 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
42GF Score

Get the complete analysis for ROCO:6986

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.35
Price
NT$110.18
GF Value